Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2754579 | Clinical Lymphoma Myeloma and Leukemia | 2013 | 8 Pages |
BackgroundMyelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions.Patients and MethodsWe investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89).ResultsMultivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS.ConclusionsPatients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.